Shorter infusion may be just as good for preventing repeat variceal bleeding

NCT ID NCT03624517

Terminated Disease control Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving the drug octreotide for 24 hours instead of the usual 72 hours could prevent early rebleeding from esophageal varices in people with cirrhosis. The trial included 34 adults with active bleeding from varices who underwent endoscopic banding. The goal was to see if the shorter infusion was safe and effective, but the study was stopped early, so the findings are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: octreotide
What this could lead to: If successful, this could show that a shorter 24-hour octreotide infusion is just as safe and effective as the standard 72-hour regimen, potentially reducing hospital stay and treatment burden.
What could go wrong: The trial was terminated early with only 34 participants, so results are limited and may not be reliable. It is unclear if the shorter infusion truly prevents rebleeding as well as the longer one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLEEDING ESOPHAGEAL VARICES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver esophageal varices Gastrointestinal Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLEEDING ESOPHAGEAL VARICES ESOPHAGEAL VARICES LIVER CIRRHOSES UPPER GASTROINTESTINAL BLEEDING

Contacts and locations

Locations

Brooke Army Medical Center

Houston, Texas, 78234, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Texas Tech University Health Sciences Center

El Paso, Texas, 79905, United States
The Ohio state University

Columbus, Ohio, 43210, United States
The University of Texas at Austin

Austin, Texas, 78712, United States
University of Florida Health

Jacksonville, Florida, 32209, United States
University of Illinois at Chicago

Chicago, Illinois, 60607, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.